

VYVGART® Hytrulo

(efgartigimod alfa and
hyaluronidase-qvfc)

Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

In-Office Subcutaneous Injection Guide

**VYVGART Hytrulo offers a ~30 to 90-second
subcutaneous injection***

VYVGART Hytrulo can be given at an infusion center,
doctor's office, or at home.†

Get information about what to expect for the in-office injection process:
before, during, and after.

*For at least 30 minutes after your injection, a healthcare professional will monitor you for reactions.

†In some cases, VYVGART Hytrulo may also be given at home by a trained nurse.

gMG=generalized myasthenia gravis

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

SELECT IMPORTANT SAFETY INFORMATION


Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART HYTRULO for subcutaneous injection](#).

VYVGART Hytrulo dosing—make the most out of a treatment plan that’s designed for you

VYVGART Hytrulo is given in treatment cycles with a personalized break between each cycle

Each treatment cycle is 4 treatments, 1 given each week.



You'll **work with your doctor to personalize your breaks** between cycles based on your symptoms and side effects.



When your symptoms start to return, **talk to your doctor** to help them decide when you need another cycle.

The safety of starting the next treatment cycle sooner than 4 weeks from the last treatment of the previous treatment cycle has not been established. If you miss a scheduled treatment, VYVGART Hytrulo may be given up to 3 days after the scheduled treatment day.

Personalized breaks may help you get the most out of your treatment plan. Learn about real patients' breaks between cycles on [VYVGARTDosing.com](https://www.vyvgartdosing.com).

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART HYTRULO for subcutaneous injection](https://www.vyvgartdosing.com).

BEFORE YOUR INJECTION

VYVGART® Hytrulo

(efgartigimod alfa and
hyaluronidase-qvfc)

Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

THE DAY BEFORE YOUR SUBCUTANEOUS INJECTION, YOU MAY WANT TO:

- Prepare for your visit. You may need to find a ride if you can't drive yourself, and you should plan to get to your appointment at least 15 minutes early
- Consider wearing clothing that's loose around the waist on the day of your injection
- Bring a list of your current medications to your appointment

KEEP IN MIND: HOW TO PASS THE TIME

VYVGART Hytrulo takes about 30 to 90 seconds to inject, but your healthcare provider will monitor you for reactions for at least 30 minutes after your injection. You may want to bring something to do while you wait.



Book



Crossword



TV show



Podcast



Game

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART HYTRULO for subcutaneous injection](#).

THE 5 STEPS OF YOUR VYVGART HYTRULO SUBCUTANEOUS INJECTION

01 | Check in

Once you get to your treatment location, check in with the staff and confirm your insurance information.

02 | Get ready for injection

An office staff member will help get you ready for your subcutaneous injection. VYVGART Hytrulo may also be prepared for injection at this time.

03 | Receive your injection

A healthcare professional will inject VYVGART Hytrulo subcutaneously into an area of pinched skin on your abdomen over 30 to 90 seconds. A different area of your abdomen will be used for subsequent injections of VYVGART Hytrulo.

04 | Stay for monitoring

You will be monitored for injection site reactions and other side effects for at least 30 minutes after your injection. Consider bringing something to pass the time.

05 | Check out

Before you leave, make sure to confirm or schedule your next appointment. If this is the last injection of your treatment cycle, you may want to have a plan in place with your doctor for symptom tracking.



Not actual size

AFTER YOUR INJECTION

VYVGART® Hytrulo

(efgartigimod alfa and
hyaluronidase-qvfc)

Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

**AFTER STARTING VYVGART HYTRULO, TRACK YOUR SYMPTOMS
EACH WEEK TO HELP YOUR NEUROLOGIST DETERMINE YOUR
PERSONALIZED BREAKS.**



Scan the QR code or visit [gMSymptomTracker.com](https://gmsymptomtracker.com)
to find a symptom tracking tool that may help with
your VYVGART Hytrulo journey.

ARE YOU ENROLLED IN THE VYVGART PATIENT SUPPORT PROGRAM?

My VYVGART® *Path*

With My VYVGART Path, a Nurse Case Manager is waiting to help you throughout your VYVGART Hytrulo treatment journey. **Talk with your doctor** and ask to be enrolled in My VYVGART Path, **or visit MyVYVGARTPath.com to download the form.**

Already enrolled? Reach out to a Nurse Case Manager
for support at **1-833-MY-PATH-1 (1-833-697-2841).**

SELECT IMPORTANT SAFETY INFORMATION

VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART HYTRULO for subcutaneous injection.](#)

IMPORTANT SAFETY INFORMATION

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART HYTRULO may cause serious side effects, including:

- **Infection.** VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
- **Allergic Reactions (hypersensitivity reactions).** VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
- **Infusion-Related Reactions.** VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART HYTRULO, tell your doctor if you:

- take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
- have received or are scheduled to receive a vaccine (immunization), or
- have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

[Please see full Prescribing Information for VYVGART HYTRULO for subcutaneous injection.](#)

VYVGART® Hytrulo

(efgartigimod alfa and
hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

VYVGART Hytrulo is a trademark of argenx.

For U.S. audiences only.

©2024 argenx US-ESC-23-00178 V3 06/2024

argenx 